ATE482694T1 - Zusammensetzung zur kontrollierten wirkstoffabgabe - Google Patents

Zusammensetzung zur kontrollierten wirkstoffabgabe

Info

Publication number
ATE482694T1
ATE482694T1 AT03738316T AT03738316T ATE482694T1 AT E482694 T1 ATE482694 T1 AT E482694T1 AT 03738316 T AT03738316 T AT 03738316T AT 03738316 T AT03738316 T AT 03738316T AT E482694 T1 ATE482694 T1 AT E482694T1
Authority
AT
Austria
Prior art keywords
active compound
particles
composition
coated
active ingredients
Prior art date
Application number
AT03738316T
Other languages
English (en)
Inventor
Christopher J Speirs
Peter Moir
Richard Williams
Michael Clark
Original Assignee
Temrel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30117101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE482694(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0215656A external-priority patent/GB0215656D0/en
Priority claimed from GB0215657A external-priority patent/GB0215657D0/en
Application filed by Temrel Ltd filed Critical Temrel Ltd
Application granted granted Critical
Publication of ATE482694T1 publication Critical patent/ATE482694T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03738316T 2002-07-05 2003-07-04 Zusammensetzung zur kontrollierten wirkstoffabgabe ATE482694T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0215656A GB0215656D0 (en) 2002-07-05 2002-07-05 Controlled release composition
GB0215657A GB0215657D0 (en) 2002-07-05 2002-07-05 Controlled release composition for the treatment of inflammatory bowel disease
PCT/GB2003/002911 WO2004004696A1 (en) 2002-07-05 2003-07-04 Controlled release composition

Publications (1)

Publication Number Publication Date
ATE482694T1 true ATE482694T1 (de) 2010-10-15

Family

ID=30117101

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03738316T ATE482694T1 (de) 2002-07-05 2003-07-04 Zusammensetzung zur kontrollierten wirkstoffabgabe

Country Status (15)

Country Link
US (4) US20060127484A1 (de)
EP (1) EP1519717B1 (de)
JP (1) JP2005532387A (de)
CN (1) CN1665490A (de)
AT (1) ATE482694T1 (de)
AU (1) AU2003244840C1 (de)
BR (1) BR0312347A (de)
CA (1) CA2491355A1 (de)
DE (1) DE60334378D1 (de)
DK (1) DK1519717T3 (de)
MX (1) MXPA05000128A (de)
NZ (1) NZ537632A (de)
PL (1) PL374922A1 (de)
RU (1) RU2336865C2 (de)
WO (1) WO2004004696A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
KR20060129303A (ko) 2003-12-23 2006-12-15 템렐 리미티드 약제학적 조성물을 위한 펠렛을 생산하는 방법
US9875508B1 (en) 2004-11-19 2018-01-23 Allstate Insurance Company Systems and methods for customizing insurance
US10282785B1 (en) 2004-11-19 2019-05-07 Allstate Insurance Company Delivery of customized insurance products and services
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
CA2882048C (en) 2006-02-03 2020-03-24 Opko Renal, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
DK1993357T3 (da) * 2006-02-09 2014-04-22 Alba Therapeutics Corp Formuleringer af en tight junction effektor
AU2012203787B2 (en) * 2006-02-09 2014-07-10 Alba Therapeutics Corporation Formulations for a Tight Junction Effector
HUE037309T2 (hu) 2006-06-21 2018-08-28 Opko Ireland Global Holdings Ltd Terápia D-vitamin telítési szer alkalmazásával és D-vitamin hormon helyettesítõ szer
US20090069247A1 (en) 2006-10-06 2009-03-12 Blake Paterson Use of tight junction antagonists to treat inflammatory bowel disease
US8034776B2 (en) 2006-10-26 2011-10-11 Alba Therapeutics Corporation Materials and methods for the treatment of celiac disease
US20080292695A1 (en) * 2006-12-01 2008-11-27 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
CA2683514C (en) 2007-04-25 2019-07-09 Proventiv Therapeutics, Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
WO2009047644A2 (en) 2007-04-25 2009-04-16 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
ES2401205T3 (es) 2007-04-25 2013-04-17 Cytochroma Inc. Composiciones de orales de liberación controlada que comprende un compuesto de vitamina D y un soporte céreo
GB0712316D0 (en) * 2007-06-26 2007-08-01 Entripneur Ltd A novel powder and its method of manufacture
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
KR101685031B1 (ko) 2008-04-02 2016-12-09 사이토크로마 인코포레이티드 비타민 ｄ 결핍 및 관련 장애에 유용한 방법, 조성물, 용도 및 키트
CA2742680C (en) * 2008-11-07 2013-12-31 Samyang Corporation Pharmaceutical compositions for release control of methylphenidate
WO2010077732A2 (en) * 2008-12-09 2010-07-08 Aether Medical Llc Implantable analgesic
EP2298321A1 (de) * 2009-08-26 2011-03-23 Nordic Pharma Neuartige pharmazeutische Zusammensetzungen zur Behandlung von IBD
US20110183032A1 (en) * 2010-01-15 2011-07-28 Kemin Industries, Inc. Stomach-proected Alpha-amylase to Improve the Utilization of Diet Energy and Growth Performance of Animals
CN103037902A (zh) 2010-03-29 2013-04-10 赛特克罗公司 用于降低甲状旁腺水平的方法和组合物
KR101423237B1 (ko) * 2010-05-04 2014-07-30 주식회사 삼양바이오팜 탐스로신 또는 이의 약학적으로 허용 가능한 염을 포함하는 방출 제어용 약학 조성물, 및 이를 포함하는 경구용 제제
AU2012253834B2 (en) * 2011-05-06 2016-06-16 Glaxosmithkline Consumer Healthcare (Uk) Ip Limited Sustained release paracetamol formulations
US8951996B2 (en) * 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US10653631B2 (en) 2011-09-07 2020-05-19 Roland SAUR-BROSCH Optimal colon targeting technology
JP2014529630A (ja) * 2011-09-07 2014-11-13 ザウラー−ブロシュ、ローラント 哺乳類の消化管における一つあるいは複数の物質の放出制御製剤
GB201210184D0 (en) * 2012-06-11 2012-07-25 Univ Leuven Kath Formulations of metronidazole for the treatment of pouchitis
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
EP3162362A1 (de) * 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
EP4596045A3 (de) 2016-03-28 2025-10-15 EirGen Pharma Ltd. Verfahren zur behandlung von vitamin d
JP7750644B2 (ja) * 2016-11-09 2025-10-07 エンジーン，インコーポレイティド プログラム細胞死リガンド１の腸管発現
AU2017378393B2 (en) * 2016-12-14 2023-03-09 Bt Bidco, Inc. Treatment of a disease of the gastrointestinal tract with a TNF inhibitor
CN110072519A (zh) * 2016-12-14 2019-07-30 普罗根尼蒂公司 使用jak抑制剂治疗胃肠道疾病及装置
KR20190095936A (ko) * 2016-12-14 2019-08-16 프로제너티, 인크. 인테그린 저해제로의 위장관 질환의 치료
CN108822816A (zh) * 2018-06-25 2018-11-16 中国石油集团渤海钻探工程有限公司 一种疏松砂岩用可酸溶凝胶堵漏剂及其制备方法
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법
CN113318090A (zh) * 2021-05-26 2021-08-31 武汉新联大生物有限公司 一种阿苯达唑伊维菌素肠溶缓释微丸及其制备方法
CN113929807B (zh) * 2021-06-25 2022-09-27 贵州省欣紫鸿药用辅料有限公司 一种烯烃酸树脂及其制备方法
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001800A1 (en) * 1991-07-24 1993-02-04 Thomas Sai Ying Ko Therapeutic compositions and methods
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
GB2292079B (en) * 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
US5834024A (en) * 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
JPH1067657A (ja) * 1996-06-18 1998-03-10 Otsuka Pharmaceut Co Ltd マルチプルユニット型持続性製剤
DE19652183C1 (de) * 1996-12-14 1998-02-12 Schaper & Bruemmer Gmbh Verwendung eines Extraktes aus Cimicifuga racemosa
DE19724696A1 (de) * 1997-06-12 1998-12-24 Hexal Ag Pharmazeutische Zubereitung mit drei Pelletarten
DE19901686A1 (de) * 1999-01-18 2000-07-20 Gruenenthal Gmbh Retardierte Tramadolzubereitungen mit einem lagerstabilen Freisetzungsprofil und Verfahren zu deren Herstellung
EP1064938A1 (de) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmazeutische Dosierungsformen zur kontrollierte Wirkstoffabgabe mit mindenstens ein pulsierendem Zeitverlauf
EP2283829A1 (de) * 2000-10-30 2011-02-16 Euro-Celtique S.A. Hydrocodon-Formulierungen mit gesteuerter Freisetzung
RU2276998C2 (ru) * 2001-05-01 2006-05-27 Институт Нефтехимического Синтеза Имени А.В. Топчиева Российской Академии Наук Гидрогелевые композиции

Also Published As

Publication number Publication date
AU2003244840C1 (en) 2010-03-04
CA2491355A1 (en) 2004-01-15
MXPA05000128A (es) 2005-09-30
US20060127484A1 (en) 2006-06-15
DK1519717T3 (da) 2011-01-10
US20130230588A1 (en) 2013-09-05
US20110182986A1 (en) 2011-07-28
DE60334378D1 (de) 2010-11-11
EP1519717B1 (de) 2010-09-29
BR0312347A (pt) 2005-04-12
AU2003244840A1 (en) 2004-01-23
US20140322317A1 (en) 2014-10-30
AU2003244840B2 (en) 2009-09-10
RU2005102838A (ru) 2005-08-10
PL374922A1 (en) 2005-11-14
WO2004004696A1 (en) 2004-01-15
RU2336865C2 (ru) 2008-10-27
JP2005532387A (ja) 2005-10-27
NZ537632A (en) 2006-06-30
CN1665490A (zh) 2005-09-07
EP1519717A1 (de) 2005-04-06

Similar Documents

Publication Publication Date Title
DE60334378D1 (de) Zusammensetzung zur kontrollierten wirkstoffabgabe
MXPA02007762A (es) Sistema de suministro de farmaco pulsativos temporalizados.
AP2002002553A0 (en) Hydrogel-driven Drug Dosoge Form.
BR0103033A (pt) Partìculas farmacêuticas de sabor mascarado
WO2004043513A3 (en) Surface dissolution and/or bulk erosion controlled release compositions and devices
ATE295155T1 (de) Beschichtungen mit immobilisierten partikeln sowie verwendungen derselben
DK2332523T3 (da) Ensartede film til hurtigtopløsende doseringsform indeholdende smagsmaskerende præparater
MXPA03012041A (es) Sistema de administracion controlada de farmacos de retencion gastrica.
CY1112517T1 (el) Φαρμακοτεχνικες μορφες τροποποιημενης αποδεσμευσης μιας τουλαχιστον μορφης τραμαδολης
ATE230426T1 (de) Überzugs- und bindemittel für orale oder dermale arzneiformen
NO20043716L (no) Farmasoytisk tablett
DE502005003223D1 (de) Multipartikuläre arzneiform für wenig lösliche wirkstoffe sowie ein verfahren zur herstellung der arzneiform
AU2002254036A1 (en) Taste masked pharmaceutical compositions
DE69917866D1 (de) Bupropionhydrochlorid enthaltende Tabletten mit gesteuerter Wirkstoffabgabe
EA200600598A1 (ru) Лекарственные формы замедленного высвобождения
DK0868912T3 (da) Anvendelse af redispergerbare polymerpulvere eller polymergranulater til coating af farmaceutiske eller agrokemiske applikationsformer
MY148867A (en) Gastric retention drug delivery system
IL173078A0 (en) Multiparticle pharmaceutical dosage form containing a mucoadhesively formulated peptide or protein active substances method for producing said pharmaceutical dosage form
EP1803448A3 (de) Geschmacksüberdeckte feste Arzneiformen für Tiere
HUP0203813A3 (en) Aminobenzophenones as inhibitors of il-1betha and tnf-alpha, pharmaceutical compositions containing them and their use
DK1453487T3 (da) Farmaceutisk doseringsform med flere belægninger for reduceret virkning af belægningsbrud
ATE407674T1 (de) Orale pharmazeutische formulierung in form einer wässrigen suspension von mikrokapseln zur modifizierten freisetzung von amoxicillin
GEP20043285B (en) Sustained Release Beadlets Containing Stavudine, Method for Their Production, Pharmaceutical Composition Containing the Same and Use Thereof for Treatment Retroviral Infections
MX2009000849A (es) Formas de dosificacion liofilizadasdisolvibles oralmente/desintegrables que contienen particulas protegidas.
NO20075715L (no) Depotsammensetning omfattende cefalosporin for behandling av en bakterieinfeksjon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties